The coupling of inhibitors against BRAF/MEK, BRAF/JNK, MEK/Plk1, MEK/pan-RAF, and PI3K/MAPK have been explored as promising approaches; however, these strategies only uncover a fraction of the therapeutic potential contained in combinatory treatment of melanoma. The gene discussed is PLK1; the disease is melanoma.